Interleukin 4 plasma levels in psoriasis vulgaris patients

Medical Science Monitor

Volumn 10, Issue 4, 2004, Pages

  Zalewska, Anna ^a   Wyczółkowska, Janina ^b   Dzlankowska Bartkowlak, Bozena ^a   Sysa Jȩdrzejowska, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Interleukin 4; Psoriasis vulgaris; Th1 cell response; Th2 type response

Indexed keywords

CYTOKINE; INTERLEUKIN 4;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; PROTEIN BLOOD LEVEL; PSORIASIS VULGARIS; STATISTICAL SIGNIFICANCE; TREATMENT INDICATION;

ADULT; ANTHRALIN; FEMALE; FICUSIN; HUMANS; INTERLEUKIN-4; MALE; METHOTREXATE; MIDDLE AGED; PHOTOTHERAPY; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 1942438943     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Chomarat P, Banchereau J: An update on interleukin-4 and its receptor. Eur Cytokine Netw, 1997; 8: 333-44
2. Atamas SP, White B: Interleukin 4 in systemic sclerosis: not just an increase. Clin Diag Lab Immunol, 1999; 6: 658-59
3. Craven NM, Jackson CW, Kirby B et al: Cytokine gene polymorphisms in psoriasis. Br J Dermatol, 2001; 144: 849-53
4. Griffiths CEM: The immunological basis of psoriasis. J Eur Acad Dermatol Venereol, 2003; 17(Suppl 2): 1-5
5. Christophers E: Psoriasis: epidemiology and clinical spectrum. Clin Exp Dermatol, 2001; 26: 314-20
6. Schlaak JF, Buslau M, Jochum W et al: T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol, 1994; 102: 145-49
7. Vollmer S, Menssen A, Trommler P et al: T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol, 1994; 24: 2377-82
8. Huang BB, Bonish BK, Chaturvedi V et al: Keratinocyte CDw60 expression is modulated by both a Th-1 type cytokine IFN-gamma and Th-2 cytokines IL-4 and IL-13: relevance to psoriasis. J Invest Dermatol, 2001; 116: 305-12
9. Kagi KM, Wuthrich B, Montano E et al: Differential cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals. Int Arch Allergy Immunol, 1994; 103: 332-40
10. Asadullah K, Sterry W, Stephanek K et al: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest, 1998; 101: 783-94
11. Rowe A, Bunker CB: Interleukin-4 and the interleukin-4 receptor in allergic contact dermatitis. Contact Dermatitis, 1998; 38: 36-39
12. Thomas P: IL-4 induced immune deviation as therapy of psoriasis [abstract]. Arch Dermatol Res, 2001; 293: 30
13. Bradbury J: 'Immune deviation' with IL-4 could prove beneficial in psoriasis. Lancet, 2002; 360: 1845
14. Ghoreschi K, Mrowietz U, Rocken M: A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med, 2003; 81: 471-80
15. Ghoreschi K, Thomas B, Breit S et al: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med, 2003; 9: 40-46
16. Fredriksson T, Pettersson U: Severe psoriasis - oral therapy with a new retinoid. Dermatologica, 1978; 157: 238-44
17. Finkelman FD, Urban JF: The other side of the coin: the protective role of Th2 cytokines. J Allergy Clin Immunol, 2001; 107: 772-80
18. Giustizieri ML, Mascia F, Frezzolini A et al: Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol, 2001; 107: 871-77
19. Yamazaki F, Aragane Y, Maeda A et al: Overexpression of IL-4-induced activator protein-1 in atopic dermatitis. J Dermatol Sci, 2002; 28: 227-33
20. Elbe-Bürger A, Egyed A, Olt S et al: Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol, 2002; 118: 767-78
21. Stern RS: Psoriasis. Lancet, 1997; 350; 349-53
22. Cancino-Díaz JC, Reyes-Maldonado E, Banuelos-Pánuco CA et al: Interleukin-13 receptor in psoriatic keratinocytes: overexpression of the mRNA and underexpression of the protein. J Invest Dermatol, 2002; 119: 1114-20
23. Szegedi A, Aleksza M, Gonda A et al: Elevated rate T helper1 (T(H)1) lymphocytes and serum IFN-gamma levels in psoriasis patients. Immunol Lett, 2003; 86: 277-80
24. Prens E, Hegmans J, Lien RCA et al: Increased expression of interleukin-4 receptors on psoriatic epidermal cells. Am J Pathol, 1996; 148: 1493-502
25. Trepicchio WL, Ozawa M, Walters IB et al: Interleukin-11 therapy selectively downregulates type 1 cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest, 1999; 104: 1527-37
26. Asadullah K, Eskdale J, Wiese A et al: Interleukin-10 promoter polymorphism in psoriasis. J Invest Dermatol, 2001; 116: 975-78
27. Asadullah K, Friedrich M, Hanneken S: Effects of systemic intereukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J Invest Dermatol, 2001; 116: 721-27
28. Kirby B, Griffiths CEM: Psoriasis: the future. Br J Dermatol, 2001; 144(Suppl. 58): 37-43
29. Al-Salem IH: Striking and rapid improvement of plaque psoriasis with infliximab. Dermatology, 2003; 207: 54-56
30. Oh CJ, Das KM, Gottlieb AB: Treatment with anti-tumor necrosis factor alpha (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol, 2000; 42(5 Pt 1): 829-830
31. Litjens NHR, Nibbering PH, Barroís AJ et al: Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol, 2003; 148: 444-51
32. Mozzanica N, Cattaneo A, Trabattoni D et al: Production of type-1 and type-2 cytokines by peripheral blood mononuclear cells of psoriatic patients. Immunology, 1995; 86: 422-26
33. Klosner G, Trautinger F, Knobler R, Neuner P: Treatment of peripheral blood mononuclear cells with 8-methoxypsolaren plus ultraviolet A radiation induces a shift in cytokine expression from a Th1 to a Th2 response. J Invest Dermatol, 2001; 116: 459-62
34. Piskin G, Tursen U, Bos JD, Teunissen MBM: IL-4 expression by neutrophils in psoriasis lesional skin upon high-dose UVB exposure. Dermatology, 2003; 207: 51-53
35. Piskin G, Koomen CW, Picavet D et al: Ultraviolet-B radiation decreases IFN-gamma and increases IL-4 expression in psoriatic lesional skin in situ and cultured dermal T cells derived from these lesions. Exp Dermatol, 2003; 12: 172-80
36. Asadullah K, Volk H-D, Friedrich M, Sterry W: Experimental therapies for psoriasis. Arch Immunol Ther Exp, 2002; 50: 411-20
37. Singri P, West DP, Gordon KB: Biologic therapy for psoriasis. The new therapeutic frontier. Arch Dermatol, 2002; 138: 657-63
38. Reich K, Garbe C, Blaschke V et al: Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interelukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol, 2001; 116: 319-29
39. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum levels of interleukin 4 (IL-4), IL-10 and IL-13 in patients with systemic sclerosis. J Rheumatol, 1997; 24: 328-32
40. Asadullah K, Volk H-D, Sterry W: Novel immunotherapies for psoriasis. Trends Immunol, 2002; 23: 47-53
41. Gottlieb A: Immunologic agents for the treatment of psoriasis. Arch Dermatol, 2003; 139: 791-93
42. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H: Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol, 2004; 135: 1-8